ISO 13485:2016 Audit Checklist

medical lab pharma

Table of Contents

Share

medical lab pharma
TL;DR
  • This free ISO 13485 audit checklist covers clauses 4 through 8 of ISO 13485:2016, which ISO reconfirmed in 2025 as the current edition.
  • Mark each item Compliant, Partial, Not compliant, or N/A; your progress saves in this browser, and the summary builds your gap list automatically.
  • US manufacturers: the FDA's QMSR took effect February 2, 2026 and incorporates ISO 13485:2016 by reference, but adds FDA-specific requirements. Switch on the optional QMSR section to check them.
  • Use it for internal audits, supplier audits, and certification readiness. It does not replace the standard itself or a qualified auditor.

ISO 13485:2016 Audit Checklist

Medical device QMS audit checklist: clauses 4 to 8, with optional FDA QMSR checks

0 of 0 items assessed

Audit summary

Gaps to close

Need help closing the gaps?

DES Pharma supports quality system remediation, CAPA, supplier qualification, and audit readiness for drug, biologic, and combination product teams.

Talk to our quality team

Audit questions are paraphrased by DES Pharma and reference ISO 13485:2016 clause numbers only. They are not the text of the standard. Obtain the full standard from ISO or your national standards body for authoritative requirements.

Who needs an ISO 13485 audit?

Any organization that designs, manufactures, sterilizes, distributes, installs, or services medical devices, or supplies components and services to companies that do, can be audited against ISO 13485. That includes contract manufacturers, sterilization providers, software developers whose products qualify as devices, and pharma or biotech companies building drug-device combination products such as prefilled syringes, autoinjectors, and on-body injectors.

The standard is the backbone of device regulation in many markets. It is the audit basis for the Medical Device Single Audit Program (MDSAP), it underpins QMS expectations under the EU MDR and IVDR, and since February 2026 it forms the core of the FDA's device quality rule. ISO lists the 2016 edition as confirmed after its 2025 systematic review, so this checklist is built on the edition that remains in force.

Internal audits vs certification audits

Internal auditCertification audit
Who runs itYour own trained auditors or a consultant, independent of the area audited (clause 8.2.4)An accredited certification body (notified body or MDSAP auditing organization)
PurposeFind and fix weaknesses before anyone else doesIssue or maintain a certificate
CadencePlanned intervals, weighted toward high-risk processesStage 1 and Stage 2 initial audit, annual surveillance, recertification every three years
OutputFindings feed CAPA and management reviewMajor and minor nonconformities with deadlines for correction

A strong internal audit program is your best predictor of a clean certification audit. Auditors read your internal audit records to judge whether your QMS can find its own problems.

How to use this checklist

  1. Set the scope. Fill in the site and processes covered. Mark clauses that do not apply, such as sterile device or implantable requirements, as N/A, and document the justification in your quality manual.
  2. Audit with evidence. For each question, sample real records: a CAPA file, a supplier evaluation, a training matrix. A procedure alone does not prove compliance.
  3. Grade honestly. Use Partial when a process exists but is inconsistent or poorly recorded. Add a note naming the evidence you reviewed.
  4. Act on the gap list. The summary sorts Not compliant items first. Feed each one into your CAPA system with an owner and due date, then print the report for management review.

Your answers save automatically in this browser only. Nothing is sent to DES Pharma.

The most common ISO 13485 nonconformities

Certification body findings and FDA inspection observations cluster in the same few areas year after year:

  • CAPA (8.5.2, 8.5.3): root cause stops at "human error," actions are not verified for effectiveness, or CAPAs stay open for months.
  • Complaint handling (8.2.2): complaints closed without investigation or a documented reason, and reportability decisions not recorded.
  • Supplier control (7.4): no risk-based criteria for selecting and monitoring suppliers, and quality agreements missing for critical outsourced processes.
  • Process validation (7.5.6): special processes such as sealing, molding, or bonding run without validation, or changes made without revalidation.
  • Design controls (7.3): weak traceability from inputs to outputs, and design changes not assessed against risk management.
  • Software validation (4.1.6, 7.5.6): QMS and production software, including spreadsheets and eQMS platforms, used without documented validation.
  • Management review (5.6): required inputs missing and outputs lacking concrete decisions.

Pharma teams moving into combination products often stumble on design controls and supplier management, which drug CGMP handles differently. Our quality assurance team sees this pattern frequently.

What the FDA QMSR means for US manufacturers

The FDA's Quality Management System Regulation became effective on February 2, 2026. It replaces the old Quality System Regulation and incorporates ISO 13485:2016 by reference, so US inspections now follow the ISO clause structure. FDA also retired its QSIT inspection technique and now inspects under Compliance Program 7382.850, a risk-based approach that puts risk management at the center.

Three practical points matter. First, an ISO 13485 certificate does not exempt you from FDA inspection, and FDA does not issue ISO certificates. Second, the QMSR adds supplemental provisions on records (820.35), including complaint, servicing, and UDI details, and on labeling and packaging controls (820.45). Third, internal audit, supplier audit, and management review records are now open to FDA investigators, which they generally were not under the old rule. Turn on the QMSR toggle in the checklist to cover these points.

ISO 13485 Audit Questions We Hear Most

Is ISO 13485:2016 still the current version?

Yes. ISO completed a systematic review in 2025 and confirmed the 2016 edition without changes. Plan your QMS and audits against ISO 13485:2016; the next scheduled review would fall around 2030.

Does ISO 13485 certification mean we comply with the FDA QMSR?

No. Certification shows strong alignment, but the QMSR adds FDA-specific requirements for records, labeling and packaging, and links to other FDA rules such as medical device reporting, corrections and removals, and UDI. FDA still inspects certified firms.

How often should we run internal ISO 13485 audits?

The standard requires planned intervals based on process importance and past audit results, not a fixed frequency. Most organizations cover every clause at least once a year and audit high-risk processes, such as CAPA, complaints, and sterilization, more often.

Does ISO 13485 apply to drug-device combination products?

Often, yes. Under 21 CFR Part 4, a combination product with a device constituent must meet device quality requirements. A drug-led manufacturer can follow drug CGMP plus a defined subset of device requirements, which now point to specific ISO 13485 clauses such as management responsibility, design and development, purchasing, and CAPA.

What is the difference between a major and a minor nonconformity?

Definitions vary by certification body, but a major nonconformity usually means a required process is missing or has broken down, or nonconforming product could reach users. A minor nonconformity is an isolated lapse that does not threaten the system. Majors typically must be corrected and verified before a certificate is issued or kept.

Need help closing the gaps?

Whether you are preparing for a Stage 2 audit, responding to findings, or bringing a combination product under a device QMS, DES Pharma can help you prioritize gaps, build CAPA plans, and get audit ready.

Request a meeting

About DES Pharma. DES Pharma (Dynamic Engineering Solutions) supports drug developers from pre-clinical development through clinical manufacturing and commercialization, with services spanning program and process development, analytics and quality control, supply chain strategy, and quality assurance and GMP compliance.

Share

More Insights:

Connect With Our Team TodayAdvance Your Drug Program
with Confidence

Start building reliable, high-quality drug development programs today.